VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors [Yahoo! Finance]
VYNE Therapeutics Inc. (VYNE)
Company Research
Source: Yahoo! Finance
company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Christine Borowski, Ph.D., to its board of directors, effective as of January 1, 2024. “We are pleased to welcome Dr. Borowski to our Board of Directors during this important time in the Company's growth,” said David Domzalski, President and CEO of VYNE. “With her expertise in immunology and extensive experience in the biopharmaceutical industry, Dr. Borowski will provide valuable perspectives as we seek to execute on our strategic objectives of developing novel immuno-inflammatory therapies through our InhiBET™ platform.” Dr. Borowski has served as Vice President at Access Biotechnology, a leading healthcare investor, since January 2022, and previously served as Senior Associate beginning in July 2019. Prior to that, Dr. Borowski worked on therapeutics company creation at Apple Tree Partners. Before joining Apple Tree Part
Show less
Read more
Impact Snapshot
Event Time:
VYNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VYNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VYNE alerts
High impacting VYNE Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
VYNE
News
- VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]Yahoo! Finance
- VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceGlobeNewswire
- What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- VYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.MarketBeat
VYNE
Analyst Actions
- 2/29/24 - HC Wainwright
VYNE
Sec Filings
- 4/3/24 - Form 4
- 4/3/24 - Form 4
- 4/3/24 - Form 4
- VYNE's page on the SEC website